Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
Climb Bio, Inc. (CLYM)
Company Research
Source: GlobeNewswire
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024. About Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com. InvestorsChris Brinzey ICR Westwickechris.brinzey@westwicke.com 339-970-2843 MediaJon YuICR Westwickejon.yu@westwicke.com475-395-5375 Source: Climb Bio, Inc.
Show less
Read more
Impact Snapshot
Event Time:
CLYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLYM alerts
High impacting Climb Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CLYM
News
- Climb Bio to be Added to the Nasdaq Biotechnology IndexGlobeNewswire
- Climb Bio, Inc. (NASDAQ: CLYM) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Climb Bio, Inc. (NASDAQ: CLYM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- Climb Bio Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the BoardGlobeNewswire
CLYM
Analyst Actions
- 12/2/24 - Leerink Partners